-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, J5+E3BC5bQEqCSVR8k+lvY3AM3nLzPnh1DfN9LLOBI6aKomB/30rZ9nw6D6y4OSL whz733GAWtIx3EoRkoJgew== 0001095811-01-502708.txt : 20010613 0001095811-01-502708.hdr.sgml : 20010613 ACCESSION NUMBER: 0001095811-01-502708 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20010611 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 20010612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOTHERAPEUTICS INC CENTRAL INDEX KEY: 0000831547 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930979187 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-28782 FILM NUMBER: 1658964 BUSINESS ADDRESS: STREET 1: 157 TECHNOLOGY DR STREET 2: STE J-821 CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 9497886700 MAIL ADDRESS: STREET 1: 157 TECHNOLOGY DR STREET 2: STE J-821 CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: AMERICUS FUNDING CORP DATE OF NAME CHANGE: 19920703 8-K 1 a73384e8-k.htm 8-K Neotherapeutics Form 8-K
Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934

June 11, 2001
Date of Report (Date of earliest event reported)

NEOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)
         
Delaware
(State or other Jurisdiction
of Incorporation)		 000-28782
(Commission File Number) 		93-0979187
(IRS Employer
Identification Number)
 
157 Technology Drive
Irvine, California
(Address of principal executive offices)		 92618
(Zip Code)

(949) 788-6700
(Registrant’s telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

 

Item 7. Exhibits
Item 9. Regulation FD Disclosure
SIGNATURES
EXHIBIT INDEX
ex-99.1

Table of Contents

Item 7. Exhibits

Exhibits:

  99.1   Press Release dated June 11, 2001.

Item 9. Regulation FD Disclosure

On June 11, 2001, NeoTherapeutics, Inc. issued a news release regarding its publicly traded warrants, the text of which is set forth in Exhibit 99.1 attached to this report. Exhibit 99.1 is incorporated by reference into this report. NeoTherapeutics, Inc. is furnishing the information contained in this Current Report on Form 8-K pursuant to the Securities and Exchange Commission’s Regulation FD.

 

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
NEOTHERAPEUTICS, INC.
 
 
 
Date:    June 11, 2001 By:  /s/ Samuel Gulko
Name:     Samuel Gulko
Title: Chief Financial Officer

 

Table of Contents

EXHIBIT INDEX

Exhibits:

  99.1   Press Release dated June 11, 2001.

  EX-99.1 2 a73384ex99-1.htm EX-99.1 Exhibit 99.1 to Neotherapeutics Form 8-K

EXHIBIT 99.1
   
Contacts:
MEDIA RELATIONS
Jon Siegal
Ronald Trahan Associates (RTA) Inc.
(508) 647-9782, ext. 15		  
INVESTOR RELATIONS
John McManus
NeoTherapeutics Inc.
(949) 788-6700, ext. 247

NeoTherapeutics announces no changes will be made to terms of warrants expiring in September 2001

      IRVINE, Calif., June 11, 2001 — NeoTherapeutics, Inc. (NASDAQ: NEOT, NEOTW) announced today that its board of directors has decided not to change the terms or expiration date of the Company’s publicly traded warrants. The warrants, which trade under the symbol NEOTW, are exercisable for one share of NeoTherapeutics common stock at an exercise price of $11.40 per share and expire on September 26, 2001.

      “Should the warrants expire without being exercised, they will represent a reduction of potential dilution to the benefit of existing shareholders. Further, their extension and repricing would create an accounting charge that would negatively impact our statement of operations, in addition to the monetary costs associated with this transaction and the problematic likelihood of their exercise,” stated Alvin J. Glasky, Ph.D., Chairman and Chief Executive Officer of NeoTherapeutics. “Exercise or expiration of these warrants will clean up our capital structure, which we believe will facilitate the further evolution of our financing strategy in further preparation for our next level of investment.

      NeoTherapeutics seeks to create value for stockholders through the development of central nervous system drugs by its neurology division, in-licensing and development of anti-cancer drugs through its NeoOncoRx subsidiary, and the licensing out of new drug targets through its NeoGene Technologies subsidiary. NeoTherapeutics is a biopharmaceutical company focused on the development of drugs for unmet medical needs. The Company’s most advanced drug, Neotrofin™, is currently being developed for Alzheimer’s disease and other neurodegenerative diseases, such as Parkinson’s disease and spinal cord injury. For additional information visit the Company’s web site at www.neotherapeutics.com.

      This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company’s reports filed with the Securities and Exchange Commission.

# # #

-----END PRIVACY-ENHANCED MESSAGE-----